{"pmid":32338155,"title":"Rheumotologitsts' View on the Use of Hydroxychloroquine to Treat COVID-19.","text":["Rheumotologitsts' View on the Use of Hydroxychloroquine to Treat COVID-19.","Emerg Microbes Infect","Sun, Xiaoxuan","Ni, Yicheng","Zhang, Miaojia","32338155"],"journal":"Emerg Microbes Infect","authors":["Sun, Xiaoxuan","Ni, Yicheng","Zhang, Miaojia"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32338155","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1080/22221751.2020.1760145","keywords":["covid-19","chloroquine (cq)","sars-cov-2","hydroxychloroquine (hcq)","therapy"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1665264685520257024,"score":8.574329,"similar":[{"pmid":32320742,"title":"COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next.","text":["COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next.","Metabolism","Angelidi, Angeliki M","Belanger, Matthew J","Mantzoros, Christos S","32320742"],"journal":"Metabolism","authors":["Angelidi, Angeliki M","Belanger, Matthew J","Mantzoros, Christos S"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320742","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.metabol.2020.154245","keywords":["covid-19","diabetes","evidence-based practice","renin-angiotensin system","risk","sars-cov-2","therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087757557760,"score":85.36832},{"pmid":32314483,"title":"COVID-19 and psoriasis : should we fear for patients treated with biologics?","text":["COVID-19 and psoriasis : should we fear for patients treated with biologics?","The new coronavirus pandemic poses question and challenges for dermatologists. One of question is if psoriasis patients treated with immunomodulating and immunosuppressive drugs have to discontinue their treatment in the midts of fears for the infection and its consequences. One of the challenges is how can we support our patients in this critical time. Previous coronaviruses outbreaks reports, current published evidences on pathogenesis and on clinical reports of COVID infection in immunosuppressed patients are used to make a scientifically based decision. This article is protected by copyright. All rights reserved.","Dermatol Ther","Amerio, Paolo","Prignano, Francesca","Giuliani, Federica","Gualdi, Giulio","32314483"],"abstract":["The new coronavirus pandemic poses question and challenges for dermatologists. One of question is if psoriasis patients treated with immunomodulating and immunosuppressive drugs have to discontinue their treatment in the midts of fears for the infection and its consequences. One of the challenges is how can we support our patients in this critical time. Previous coronaviruses outbreaks reports, current published evidences on pathogenesis and on clinical reports of COVID infection in immunosuppressed patients are used to make a scientifically based decision. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Amerio, Paolo","Prignano, Francesca","Giuliani, Federica","Gualdi, Giulio"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314483","week":"202017|Apr 20 - Apr 26","doi":"10.1111/dth.13434","keywords":["biologics","covid-19","psoriasis","sars","therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664714520167186432,"score":81.4785},{"pmid":32281583,"title":"Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).","text":["Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).","Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Increasing evidence obtained from completed clinical studies indicates the prospects for chloroquine/hydroxychloroquine to treat COVID-19. More randomized control clinical studies are warranted to determine the feasibility of these two drugs in treating COVID-19.","Biosci Trends","Gao, Jianjun","Hu, Shasha","32281583"],"abstract":["Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Increasing evidence obtained from completed clinical studies indicates the prospects for chloroquine/hydroxychloroquine to treat COVID-19. More randomized control clinical studies are warranted to determine the feasibility of these two drugs in treating COVID-19."],"journal":"Biosci Trends","authors":["Gao, Jianjun","Hu, Shasha"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281583","week":"202016|Apr 13 - Apr 19","doi":"10.5582/bst.2020.03072","keywords":["covid-19","sars-cov-2","chloroquine","hydroxychloroquine"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Chloroquine","Hydroxychloroquine"],"_version_":1664636703909871617,"score":71.259865},{"pmid":32221057,"title":"Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.","text":["Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.","A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed.","Indian J Ophthalmol","Shetty, Rohit","Ghosh, Arkasubhra","Honavar, Santosh G","Khamar, Pooja","Sethu, Swaminathan","32221057"],"abstract":["A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed."],"journal":"Indian J Ophthalmol","authors":["Shetty, Rohit","Ghosh, Arkasubhra","Honavar, Santosh G","Khamar, Pooja","Sethu, Swaminathan"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221057","week":"202014|Mar 30 - Apr 05","doi":"10.4103/ijo.IJO_639_20","keywords":["covid-19","sars-cov-2","prophylaxis","therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638629676318721,"score":64.82456},{"pmid":32317431,"title":"Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.","text":["Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.","A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed.","Indian J Ophthalmol","Shetty, Rohit","Ghosh, Arkasubhra","Honavar, Santosh G","Khamar, Pooja","Sethu, Swaminathan","32317431"],"abstract":["A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed."],"journal":"Indian J Ophthalmol","authors":["Shetty, Rohit","Ghosh, Arkasubhra","Honavar, Santosh G","Khamar, Pooja","Sethu, Swaminathan"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317431","week":"202017|Apr 20 - Apr 26","doi":"10.4103/ijo.IJO_639_20","keywords":["covid-19","sars-cov-2","prophylaxis","therapy"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664815087770140672,"score":64.82456}]}